University of Maryland-founded artificial lung developer Breethe is targeting $5m for its latest round after previously raising approximately $7.8m.
The George Washington spinout had previously raised $4.1m in equity for its low-voltage implantable cardiac defibrillator.
Canada’s Strategic Innovation Fund will provide $19.2m for accelerator Creative Destruction Lab over four years with the aim of supporting more than 1,300 science-focused companies.
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
Cornell spinout Gotham Therapeutics has come out of stealth with a series A round co-led by SR One, Versant Ventures and Forbion.
Glympse Bio, a medical diagnostic sensor spinout from MIT, has secured $22m in a series A round ahead of clinical trials targeting fatty liver disease and cancer.